Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024 16:00 ET
|
Seres Therapeutics, Inc.
CAMBRIDGE, Mass, June 07, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on June 5,...
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science
June 06, 2024 06:30 ET
|
Seres Therapeutics, Inc.
Seres anticipates capital infusions, including an upfront payment, enabling the Company to fully retire its debt and extend its cash runway into Q4 2025, pending deal closure and subject to...